Rocket Pharmaceuticals, Inc. (RCKT)
| Market Cap | 2.75B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -155.22M |
| Shares Out | 61.57M |
| EPS (ttm) | -2.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 11 |
| Last Price | $39.70 |
| Previous Close | $43.35 |
| Change ($) | -3.65 |
| Change (%) | -8.42% |
| Day's Open | 40.00 |
| Day's Range | 38.30 - 41.87 |
| Day's Volume | 339,748 |
| 52-Week Range | 16.53 - 67.48 |
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
CRANBURY, N.J.--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for ra...
CRANBURY, N.J.--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for ra...
CRANBURY, N.J.--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for ra...
Reddit playing a major role in biotech trading action, says Jefferies top health care analyst
Jared Holz, Jefferies managing director and healthcare sector specialist, on which biotech stocks could be the next targets. With Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Fi...
CRANBURY, N.J.--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for ra...
NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
Rocket Pharmaceuticals' (RCKT) AAV-based gene therapy candidate demonstrates early evidence of clinical benefit and tolerability in patients with Danon disease, which affects the cardiac muscle.
NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
You don't have to be a pandemic fighter to have a big victory for investors.
NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
NEW YORK--(BUSINESS WIRE)---- $RCKT #Danon--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rar...
NEW YORK--(BUSINESS WIRE)---- $RCKT #ASH2020--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for r...
NEW YORK--(BUSINESS WIRE)---- $RCKT #ASH2020--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for r...
NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disor...
NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
NEW YORK--(BUSINESS WIRE)---- $RCKT #ESID--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare...
NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
NEW YORK--(BUSINESS WIRE)---- $RCKT #Danon--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rar...
NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
NEW YORK--(BUSINESS WIRE)---- $RCKT--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare child...
NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disor...
NEW YORK--(BUSINESS WIRE)-- #IMO--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhoo...
Rocket Pharmaceuticals: Updating Our Bullish View For Recent Events - Still A BUY
Rocket Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Rocket (RCKT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Does Rocket Pharmaceuticals (RCKT) have what it takes to be a top stock pick for momentum investors? Let's find out.
As of late, it has definitely been a great time to be an investor in Rocket Pharmaceuticals, Inc. (RCKT).
RCKT has solid pipeline assets and plenty of catalysts during next 12 months for value creation. There are no near-term funding needs.
Rocket Therapeutics has remained under my radar despite making headway in the gene therapy pipeline with multiple INDs being accepted. I review the companies technology and pipeline candidates.
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood ... [Read more...]
| Industry Biotechnology | |
| CEO Gaurav Shah | Employees 91 |
| Stock Exchange NASDAQ | Ticker Symbol RCKT |
Analyst Forecasts
According to 13 analysts, the average rating for RCKT stock is "Strong Buy." The 12-month stock price forecast is 72.90, which is an increase of 83.63% from the latest price.